Slingshot members are tracking this event:
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Sep 21, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Gs-5745, Ulcerative Colitis, Anti-mmp9 Antibody